Patel Manish R
Department of Medicine, Division of Hematology, Oncology, & Transplantation, University of Minnesota Medical Center, Minneapolis, MN 55455, USA.
Immunotherapy. 2018 Apr;10(5):383-390. doi: 10.2217/imt-2017-0148.
Immune therapy has now been incorporated into the standard of care for non-small-cell lung cancer based on randomized trials showing superiority of anti-PD1 antibodies compared with chemotherapy. Thus there is a renewed interest in immune approaches to treating lung cancer. One promising approach is with oncolytic viruses that either naturally or through engineering, preferentially infect or kill cancer cells. In preclinical models of different thoracic cancers, it has been found that these viruses can induce immune responses through multiple mechanisms. Thus, in addition to their direct cytolytic effects, oncolytic viruses can also promote antitumor immunity. This review will discuss the immune effects of oncolytic viruses lung cancers and the approaches that are underway to augment immune therapy in clinical testing.
基于随机试验显示抗PD1抗体相较于化疗具有优越性，免疫疗法现已被纳入非小细胞肺癌的标准治疗方案。因此，人们对治疗肺癌的免疫方法重新产生了兴趣。一种有前景的方法是使用溶瘤病毒，其可通过自然方式或经工程改造优先感染或杀死癌细胞。在不同胸段癌症的临床前模型中，已发现这些病毒可通过多种机制诱导免疫反应。因此，除了直接的细胞溶解作用外，溶瘤病毒还可促进抗肿瘤免疫。本综述将讨论溶瘤病毒对肺癌的免疫作用以及正在进行的增强免疫疗法的临床试验方法。
